Germany-based Boehringer Ingelheim and France-based Echosens have expanded their partnership to enhance early screening, precise diagnosis, and care access for metabolic dysfunction-associated steatohepatitis (MASH). This collaboration combines BI’s therapeutics expertise with Echosens’ diagnostics capabilities to address critical gaps in disease awareness and clinical adoption.
Collaboration Objectives
The partnership aims to improve education among patients, healthcare providers, and policymakers on the importance of early MASH screening. It also seeks to streamline care pathways through cross-institutional collaboration and promote non-invasive technologies (NITs) for MASH management.
Key Initiatives
Key initiatives include enhancing disease awareness, fostering collaboration across healthcare specialties, and supporting the use of NITs like Echosens’ FibroScan. This non-invasive liver assessment tool is currently aiding BI’s survodutide in Phase III trials. Survodutide, a dual glucagon/GLP-1 receptor agonist licensed from Zealand Pharma, shows promise as a novel therapy for MASH and related metabolic disorders.-Fineline Info & Tech
